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Abstract
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible
for tumor initiation, conferring therapy resistance and tumor recurrence. In brain CSC, the PI3-K/AKT and the RAS/
mitogen activated protein kinase (MAPK) pathways are found to be activated. In consequence, the human
transcription factor YB-1, knowing to be responsible for the emergence of drug resistance and driving adenoviral
replication, is phosphorylated and activated. With this knowledge, YB-1 was established in the past as a biomarker
for disease progression and prognosis. This study determines the expression of YB-1 in glioblastoma (GBM)
specimen in vivo and in brain CSC lines. In addition, the capacity of Ad-Delo3-RGD, an YB-1 dependent oncolytic
adenovirus, to eradicate CSC was evaluated both in vitro and in vivo.
Methods: YB-1 expression was investigated by immunoblot and immuno-histochemistry. In vitro, viral replication as
well as the capacity of Ad-Delo3-RGD to replicate in and, in consequence, to kill CSC was determined by real-time
PCR and clonogenic dilution assays. In vivo, Ad-Delo3-RGD-mediated tumor growth inhibition was evaluated in an
orthotopic mouse GBM model. Safety and specificity of Ad-Delo3-RGD were investigated in immortalized human
astrocytes and by siRNA-mediated downregulation of YB-1.
Results: YB-1 is highly expressed in brain CSC lines and in GBM specimen. Efficient viral replication in and virus-
mediated lysis of CSC was observed in vitro. Experiments addressing safety aspects of Ad-Delo3-RGD showed that
(i) virus production in human astrocytes was significantly reduced compared to wild type adenovirus (Ad-WT) and
(ii) knockdown of YB-1 significantly reduced virus replication. Mice harboring othotopic GBM developed from a
temozolomide (TMZ)-resistant GBM derived CSC line which was intratumorally injected with Ad-Delo3-RGD survived
significantly longer than mice receiving PBS-injections or TMZ treatment.
Conclusion: The results of this study supported YB-1 based virotherapy as an attractive therapeutic strategy for
GBM treatment which will be exploited further in multimodal treatment concepts.
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GBM is among the most deadly human cancers. Despite
modern diagnosis and improved treatment regimens,
including surgical resection followed by radiation and
chemotherapy with TMZ, the prognosis for patients with
GBM remains poor with a median survival after diagnosis
of less than 15 months [1,2]. Thus, new GBM therapeutic
strategies are desperately needed. Considerable research
efforts have been focused on dissecting the role of cancer
stem cells (CSC) also referred to as tumor initiating cells
(TIC), in cancer progression and recurrence [3,4]. CSC
have been described in several tumor types, including
GBM [5,6]. A number of studies have explored their role
in overall tumor treatment resistance producing contra-
dictory results [7-9]. Still, the detailed mechanisms of
treatment resistance have to be characterized. Neverthe-
less, it is currently believed that CSCs are responsible for
tumor initiation, progression and relapse, and that deple-
tion of these cells is obligatory to cure patients.
On the transcriptional and protein level several signal-
ing pathways, including PI3-K/AKT and the RAS/MAPK
pathway, have been identified in brain CSC [10-12]. One
of the downstream phosphorylation substrates of both
pathways is YB-1, a multifunctional protein regulating
transcription and translation [13]. However, apart from
these important results very little is known about the ex-
pression of YB-1 in CSC. The mouse homologue YB-1 is
widely expressed throughout early mouse development,
including neural tube closure and cell proliferation, but
is barely detectable in normal differentiated cells [14]. In
contrast, YB-1 is highly expressed in cancer cells, and an
increasing number of scientific articles have left little
doubt that YB-1 promotes tumor growth and drug resist-
ance [15,16]. Hence, YB-1 has been shown to be a relevant
biomarker for clinical outcome of cancer patients [17-19].
Recently, Dunn and colleagues found a link between YB-1
and breast tumor initiating cells. They reported that YB-1
induces breast cancer tumor initiating cells to express
CD44 and CD49f leading to enhanced cell growth and
drug resistance [20]. Thus, we hypothesized that YB-1 is
highly expressed in CSC derived from GBM, too. This as-
sumption is also supported by the finding that the tran-
scription factor Twist, directly involved in generating a
breast cancer stem cell phenotype, is highly expressed in
GBM [21], and promotes tumor cell growth through YB-1
expression [22]. Moreover, several essential signaling
pathways which are activated in CSC, including signal
transducer and activator of transcription (STAT)3, nuclear
factor kappa B (NFκB), PKB/AKT and MAPK/ERK are
known to target YB-1 [13,23].
Viruses that replicate selectively in tumor cells but not
in normal cells are used as agents to fight cancer. This
therapeutic approach is known as virotherapy [24]. Vari-
ous oncolytic viruses have displayed potential to efficiently
kill not only cancer cells, but also CSC [25,26]. We have
previously described the oncolytic adenovirus (OAV)
Ad-Delo3-RGD which was rendered cancer-specific by
deletion of the transactivation domain CR3 of the
E1A13S protein. This deletion restricts viral amplifi-
cation and anti-tumor activity to drug-resistant cells
displaying nuclear YB-1 expression [27]. In addition,
Ad-Delo3-RGD contains an E1B19-deletion and a RGD-
modified fiber. In a recent study, we have demonstrated
the anti-GBM efficacy of Ad-Delo3-RGD in combination
withTMZ both in vitro and in vivo [28].
Based on this knowledge and combined with the ob-
servation that high YB-1 expression and/or its nuclear
localization are closely associated with poor prognosis in
GBM and other malignancies [29,30], we hypothesize
that nuclear YB-1 protein expression due to activated
PI3-K/AKT and the RAS/MAPK pathways is signifi-
cantly elevated in brain CSC, and thus may be useful in
ablating CSC by Ad-Delo3-RGD. In the present study
we have now analyzed YB-1 protein expression in brain
CSC and non-neoplastic tissue. In addition, we exam-
ined the capacity of an YB-1 based virotherapy approach
in eradicating brain CSC in vitro and in vivo in a TMZ-
resistant GBM-CSC model.
Methods
Cell culture
U87-MG (ATCC), U373-MG and LN-18 cells (kindly pro-
vided by Dr. N. de Tribolet, Zurich, Switzerland) were
maintained in DMEM with glutamine (Biochrom, Berlin,
Germany) containing 10% FCS (PAN-Biotech, Aidenbach,
Germany). Brain CSC lines R11, R28, R40, and R49 were
obtained from patients with primary GBM as previously
described [31] and were maintained as tumorspheres in
stem cell-permissive DMEM-F12 medium supplemented
with 20 ng/ml of each human recombinant epidermal
growth factor (EGF; BD Biosciences, Heidelberg, Germany),
human recombinant basic fibroblast growth factor (bFGF;
R&D Systems, Wiesbaden, Germany), human leukemia
inhibitory factor (LIF; Millipore, Billerica, MA, USA), and
2% B27 (Life Technologies, Carlsbad, CA, USA) for pres-
ervation of the tumors’ original molecular characteristics
and for minor differentiation. SV-GA cells (a human astro-
cytic subclone of human fetal glial cells transduced with
an origin-defective mutant of simian virus 40) have been
previously described [32] and were maintained in MEM
medium with 2 mM L-glutamine, 10% fetal bovine serum,
and antibiotic solution.
Adenoviral vectors
The following viruses were used: (i) wild type adenovirus
of serotype 5 (Ad-WT), (ii) Ad-Delo3-RGD, an oncolytic
adenovirus (OAV) that combines the dl520 genotype
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anti-tumor activity to drug-resistant cells displaying
nuclear YB-1 expression) with an E1B19K deletion and a
RGD motif in the fiber knob [27], (iii) dl703 [33] that
contains expanded deletions in early region 1 (3180 bp)
and (iv) the E1A-deleted adenovirus dl312 described in
detail in [34]. All viruses were produced in HEK293 cells
and purified by two consecutive standard cesium chlor-
ide gradient centrifugations and size-exclusion chroma-
tography (PD-10 Desalting Columns, GE Healthcare,
Freiburg, Germany). Viral titers were determined by
plaque assay using HEK293 cells. Multiplicity of infec-
tion (MOI) is therefore indicated as plaque forming
units (pfu) per cell. Virus dose was optimized for each
in vitro experiment. The absence of replication compe-
tent adenovirus (RCA) in Ad-Delo3-RGD preparations
was excluded by PCR using specific primers for the
E1A-CR3 region (for primer sequences proceed to “DNA
isolation and PCR”). In general, particle (determined by
OD-measurement) to PFU ratio in virus preparation were
between 30 and 50.
Treatment with temozolomide
To calculate the EC50 of TMZ (Schering-Plough, Kenilworth,
NJ, USA) in brain CSC lines, the cells were separated by
trituation and viability was assessed by trypan blue stain-
ing. 10.000 viable brain CSC were treated with increasing
concentrations of TMZ (1–2000 μM) for 24 h followed by
a medium change. After further 72 h, cell viability was
assessed using the MTTassay.
Immunoblot analysis
Cells were lysed using ProteoJET Mammalian Cell Lysis
Reagent (Fermentas, St. Lon-Rot, Germany) supplemented
with complete protease inhibitor cocktail (Roche Diag-
nostics, Filderstadt, Germany) and incubated at room
temperature for 10 min. The lysates were clarified by
centrifugation and protein concentration was mea-
sured using the Bradford assay. 40 μg protein was sepa-
rated on SDS-polyacrylamide gels and transferred onto
poly-vinylidine-diluloride (PVDF) membranes (Millipore,
Schwalbach, Germany). For detection, the following
antibodies were used: rabbit anti-phospho-YB1 (Ser102),
rabbit PathScan® Multiplex Western Cocktail I (anti-
phospho-p90RSK, anti-phospho-AKT, anti-phospho-p44/
42 MAPK (Erk1/2), anti-phospho-S6 Ribosomal Protein
Detection Kit), rabbit anti-phospho-AKT (all antibodies
were purchase from Cell Signaling/Millipore), goat anti-
MGMT (R&D Systems) or rabbit anti-YB-1 [27]. Immu-
noreactive proteins were detected using the Amersham
enhanced chemiluminescence (ECL) or ECL plus western
blot detection system (GE Healthcare).
DNA isolation and polymerase chain reaction
For the assessment of viral replication, total DNA from
infected cells (50 MOI) was isolated using digestion buffer
(100 mM NaCl, 10 mM TrisHCl pH 8.0, 25 mM EDTA
pH 8.0, 0.5% SDS), Proteinase K and phenol-chloroform.
After precipitation with ethanol, DNA was solubilized in
10 mM TrisHCl pH 8.0. Quantitative real-time PCR was
performed using the ABI Prism 7900HT sequence detec-
tion system (Applied Biosystems) using 100 ng of total
DNA per reaction and SYBR green fluorescent dye
(Agilent Technologies, Waldbronn, Germany). The spe-
cific primers (Eurofins, Hamburg, Germany) used for real-
time PCR analyses were: fiber-fw: 5′-AAGCTAGCCCTG
CAAACATCA, fiber-rev: 5′-CCCAAGCTACCAGTGGC
AGTA, ß-actin-fw: 5′-TAAGTAGGTGCACAGTAGGTC
TGA, and ß-actin-rev: 5′-AAAGTGCAAAGAACACGG
CTAAG. For identity testing following primer were used:
12Sfw: 5’-AATGGCCGCCAGTCTTTT, 12Srev: 5’-GCCA
TGCAAGTTAAACATTATC, 13Sfw: 5’-GGCATGTTTG
TCTACAGTAAG, 13Srev: 5’-GCCATGCAAGTTAAAC
ATTATC, E1b19kfw: 5’-CGTGAGAGTTGGTGGGCGT,
E1b19krev: 5’-CTTCGCTCCATTTATCCT, E3ADPfw: 5’-
ATGTCAGCATCTGACTTTGGCC, E3ADPrev: 5’-CTC
GAGGAATCATGTCTC, E3fw: 5’-GTTAATGTCAGGTC
GCCTAAGTCG, E3rev: 5’-GTGTGTTGCCCGCGACCA
TT RGDfw: 5’-CTGCCGCGGAGACTGTTTC, RGDrev:
5’-CTGCAATTGAAAAATAAACACG. Cycling conditions
started with initial enzyme activation at 95°C for 15 min,
followed by 40 cycles of 15 sec denaturation at 95°C,
15 sec, annealing at 60°C, and 15 sec elongation at 72°C.
Homogeneity of the amplification product was confirmed
by melting curve analysis (Tm-fiber: 85°C, Tm-ß-actin:
83°C). Detection of amplification of the adenoviral se-
quences E1A12S, E1A13S, E1B19, E3, ADP and RGD
(35 cycles, annealing at 55°C) was done by agarose gel
electrophoresis.
Immunocytochemistry and immunohistochemistry
Brain CSC were grown on slides and fixed for 20 min in a
methanol/acetone (1:1) mixture at −20°C. Immunocyto-
chemical reactions were performed using rabbit anti-YB-1
antibody followed by a FITC-conjugated swine anti-rabbit
secondary antibody (1:20; Dako, Hamburg, Germany). Slides
were mounted with Vectashield (Vector Laboratories/
Axxora, Lörrach, Germany) and images were taken with
the AxioImagerZ1 with ApoTome (Zeiss Opticals,
Jena, Germany). Immunohistochemical reactions were
conducted using polyclonal rabbit antibodies directed
against YB-1 as previously described [35].
Hypoxia and clonogenic dilution assay
R11, R28 or R40 cells were seeded in 12-well plates (1 ×
10
5 cells in 0.5 ml stem cell medium per well) and infected
with the indicated viruses the next day. Cells were
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(<0.66% O2) conditions [36]. After this treatment, cells
from 12-well plates were diluted for the clonogenic dilu-
tion assay into 24-well plates containing 1ml of stem cell
medium in 1:10 dilution steps and incubated for approxi-
mately 10 doubling times (4–6 weeks).
Inhibition of YB-1 by siRNA
1.5 x 10
6 R28 cells were transfected with 1000 pmol
annealed double-strand control-siRNA (Qiagen, Hilden,
Germany; sense 5’-UUCUCCGAACGUGUCACG UdTdT-
3’ ,a n t i s e n s e5 ’-ACGUGACACGUUCGGAGAAdTdT-3’)’
or a siRNA specific for YB-1 (Qiagen; sense 5’-GGCGA
AGGUUCCCACCUUATT-3’ ,a n t i s e n s e5 ’-UAAGGUGGG
AACCUUCGCCTG-3), using Lipofectamine™ 2000 (Life
Technologies). After 24 h, cells were divided into three
aliquots and infected with 50 MOI dl703, Ad-Delo3-RGD
or Ad-WT, respectively. Cells were harvested after 4 h and
after 48 h. DNA was isolated as described above and solu-
bilized in 10 mM TrisHCl pH 8.0. Expression of YB-1 was
confirmed in cells harvested 48h after siRNA transfection
using immunoblot.
Intracranial tumor model
NMRI nude mice (Janvier, Le Genest Saint Isle, France)
were anesthetized and placed into a stereotactic fixation
device (Stoelting, Wood Dale, USA). 10
5 viable R28 cells
were injected into the right striatum. At day 7 post im-
plantation, the mice were randomly separated in 4 groups
(n=7 to 8 mice per group), followed by an intratumoral in-
jection of either PBS (mock) or 3 x 10
8 plaques forming
units( pfu) Ad-Delo3-RGD. Half of the mice were treated
intraperitoneally with TMZ (5 mg/kg) at day 10 and 17.
The mice were sacrificed when developing neurological
symptoms. Brains were isolated and fixed with 4% parafor-
maldehyde for further analysis. All animal research was
carried out in accordance with the German Animal
Welfare Act and was approved by local authorities.
Statistical analysis
If not other mentioned, figures show representative data
from at least three independent experiments. Quantitative
data were assessed using t-test. To estimate the potency of
Ad-Delo3-RGD in the animal GBM-CSC model, Kaplan-
Meier curves were prepared and log-rank analysis was
performed using SPSS16.0 (IBM, Stuttgart, Germany).
All p-values given are unadjusted, two-sided and
subjected to a significance level of 5% (* p=0.05; ** p=0.01;
*** p=0.0001).
Histopathological analysis
Tumors of mice were dissected, fixed in 4% formalde-
hyde, and embedded into paraffin. Serial 5 μm sections
were cut and stained with hematoxylin and eosin (H&E).
Histopathological evaluations were done on a light micro-
scope (Eclipse E200, Nikon Instruments, Düsseldorf,
Germany).
Results
Brain CSC lines express activated AKT and MAPK/ERK
It is established that AKT, MAPK/ERK and ribosomal
S6 kinase (RSK) can interact with and phosphorylate
YB-1 [37-39]. To explore the presence of activated AKT,
MAPK/ERK and RSK in brain CSC, we examined pro-
tein phosphorylation by immunoblot analysis (Figure 1A).
All four brain CSC lines showed phospho-AKT and
phospho-ERK expression to a different degree. Especially
striking was the phosphorylation of RSK in R11, R28
and R40 CSCs in comparison to established GBM cell
lines (U87-MG, U373-MG, LN-18). In LN-18 cells
which are characterized by high O
6-Methylguanin-
DNA-Methyltransferase (MGMT) expression and TMZ
resistance [40], phospho-AKT and phospho-ERK1/2 are
equally expressed as it is the case for the brain CSC
lines R28 and R40. In contrast to established GBM cell
lines, brain CSC lines showed no expression of phospho-S6.
MGMT is differentially expressed in brain CSC lines
TMZ resistance was reported in brain CSC [8], and dif-
ferent responsiveness to treatment with TMZ according
to the MGMT status of these cells was described [9].
Since our set of brain CSCs showed different grades of
TMZ resistance (high in R28, low in R11, intermediate
in R40 and R49; being EC50 in all CSC higher than the
clinical therapeutic TMZ concentration of ~50 μM; data
not shown), we tested MGMT expression in these cells
using immunoblot analysis. We also included the GBM
cell line LN-18 known to express MGMT and being
highly resistant to TMZ [40] as well as U87-MG and
U373-MG cells in this analysis. As shown in Figure 1B,
MGMT was detectable in LN-18, R28, R40 and R49 cell
lines, but not in U87-MG, U373-MG or R11 cells.
Brain CSC lines show high expression of YB-1
Considering YB-1 as a downstream target of PI3-K/AKT
and MAPK/RSK signaling, we next evaluated YB-1
expression in normal brain tissue, GBM cell as well as
brain CSC lines. Western blot analysis demonstrates
elevated levels of both total and phosphorylated YB-1 in
brain CSC lines and established GBM cell lines. In con-
trast, virtually no YB-1 expression was detectable in nor-
mal CNS tissue (Figure 2A right panel and Figure 2C,
upper left micrograph). Localization of YB-1 varied in
the examined brain CSC lines: In the TMZ-resistant
brain CSC line R28, YB-1 is highly phosphorylated and
located in the nucleus, whereas in R11 cells, showing
the lowest IC50 value for TMZ, YB-1 is predominately
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the weak phosphorylation status of YB-1 these cells. As
shown in Figure 2C, immunohistochemical analysis of
non-neoplastic brain tissue demonstrated no expression
of YB-1. In glioma specimen, diversifying YB-1 expres-
sion patterns could be observed. A few glioma showed
no YB-1 expression whereas in the majority of glioma
biopsies, YB-1 could be easily detected. Some glioma
exhibited cytoplasmic YB-1 expression whereas in other
GBM specimen nuclear YB-1-specific staining could be
demonstrated.
YB-1 promotes high level replication of Ad-Delo3-RGD in
brain CSC lines
We have shown that YB-1 plays an important role in the
adenoviral life cycle [41]. In addition, we have proven
that drug-resistant cells displaying nuclear YB-1 expres-
sion facilitate adenovirus replication independent of the
adenoviral E1A protein [42]. Thus, it seems reasonable to
assess the replication capacity of an YB-1 dependent
adenoviral vector in brain CSC. To exclude contamination
of Ad-Delo3-RGD preparation with an YB-1-independent
replication competent adenovirus (RCA), we analyzed all
Ad-Delo3-RGD preparations for absence of E1A13S se-
quences which are essential for YB-1 independent virus
replication [27]. As demonstrated in Figure 3A, no ampli-
fication of adenoviral DNA was measured using primers
specific for E1A13S. To analyze whether Ad-Delo3-RGD
was able to replicate in brain CSC, we infected these cells
with a E1-deleted, replication deficient adenovirus (dl703),
Ad-WT or Ad-Delo3-RGD and measured viral DNA rep-
lication by real-time PCR 4 h and 72 h post infection. As
shown in Figure 3B, Ad-Delo3-RGD replicates around
100–600 fold better than dl703, and in R40 cells even
4.3 fold better than Ad-WT, which shows slightly better
replication in the two other CSC lines (R11, R28).
Under hypoxic conditions Ad-Delo3-RGD retains its
ability to replicate (data not shown). Taken together,
these data demonstrate that Ad-Delo3-RGD replicates
efficiently in brain CSC.
Assessment of adenoviral oncolysis in brain CSC in vitro
To investigate whether Ad-Delo3-RGD induces a virus
based cytopathic effect (CPE) in infected brain CSC lines,
CPE assays were performed. As shown in Figure 3C, Ad-
Delo3-RGD infection resulted in nearly complete cytolysis
of infected brain CSC lines within 7 days, which was
confirmed by MTT assay (data not shown). In contrast
to Ad-Delo3-RGD infected brain CSC, in R28 and R49
cells expressing high levels of MGMT morphology was
not altered by treatment with TMZ. In addition, infection
of all CSC lines with the replication deficient adenovirus
dl703 did not show any lytic effect. To confirm our results
we additionally performed cell clonogenic dilution assays
with infected brain CSC lines. As shown in Figure 4 (left
panel), treatment of brain CSC lines with Ad-Delo3-RGD
considerably inhibited growth in a sustained manner
(indicated by the red color of the medium six weeks
eIF4E
phospho-ERK1/2
phospho-AKT
LN-18   U87   U373           R11   R28    R40    R49
phospho-p90RSK
phospho-S6
-tubulin
MGMT
LN-18   U87   U373             R11   R28    R40    R49 B
A
Figure 1 Brain CSC lines (R11, R28, R40, R49) display activated AKT/MAPK pathway and differential MGMT expression. (A) Immunoblot of
GBM cell lines (LN-18, U87-MG, U373-MG) and brain CSC lines (R11, R28, R40, R49) using the Multiplex PathScan antibody cocktail. ElF4E served as
loading control. (B) Immunoblot showing MGMT expression. Tubulin served as a loading control. Brain CSC lines showed differential expression of
MGMT. Of the established GBM cell lines, only LN-18 showed MGMT expression. R28 cells showed high MGMT expression and were used for the
orthotopic mouse GBM model.
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infected brain CSC, even under hypoxic conditions
(Figure 4, right panel), retain their capacity to grow and
of being metabolically active (leading to a yellow color
of the medium six weeks post infection).
Inhibition of YB-1 by siRNA reduces viral replication
The impact of YB-1 in adenoviral replication was verified
by siRNA-mediated knockdown of YB-1 in R28 cells.
Down regulation of YB-1 was demonstrated by immuno-
blot 48 h post transfection. YB-1 was down regulated to
58% in YB-1 siRNA transfected R28 cells (Figure 5A,B).
Knockdown of YB-1 in R28 cells resulted in reduced
adenoviral replication compared to control siRNA trans-
fected R28 cells (Figure 5C). 48 h after infection, copy
numbers of adenoviral vectors in YB-1 knockdown R28
cells decreased to 76% (Ad-WT) and 42% (Ad-Delo3-
RGD) in comparison to copy numbers in control
siRNA transfected cells.
Replication profile of Ad-Delo3-RGD in human astrocytes
Based on the observation that nuclear YB-1 expression
is a prerequisite of Ad-Delo3-RGD replication we sug-
gested that Ad-Delo3-RGD will be unable to replicate in
human non-dividing non-neoplastic brain cells. To con-
firm this hypothesis, we infected human immortalized
SV-GA astrocytic cells with 10 MOI of Ad-Delo3-RGD
or Ad-WT and compared particle formation in these
cells in comparison to U87MG glioma cells. Ad-WT
replication was even better in SV-GA cells compared to
U87MG glioma cells (33-fold increase), but replication
of the oncolytic adenovirus Ad-Delo3-RGD was mark-
edly and significantly reduced in SV-GA cells compared
to U87MG cells (Figure 5D).
C
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elF4E
YB-1
Phospho-YB-1
LN-18   U87   U373           R11    R28    R40    R49                P1        P2
-actin
B
DAPI                  YB-1                  Merge
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no YB-1
cytoplas. 
YB-1
nuclear 
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Figure 2 YB-1 is expressed and phosphorylated in human brain CSC lines, but not in normal CNS tissue. (A) Immunoblot of YB-1 and
phospho-YB-1. ElF4E, α-tubulin and β-actin served as loading controls. Normal brain tissue specimens were obtained from two patients (P1 + P2)
without any pathological central nervous system alterations. The amount of protein in P1 was rarely sufficient to detect phospho-YB-1 or
considerable amounts of β-actin. (B) Immunocytochemistry of R11 and R28 cells demonstrated predominantly cytoplasmic (R11) or nuclear (R28)
expression of YB-1, respectively. Blue color: DAPI staining of nuclei. Green color: YB-1 staining. (C) Immunohistochemical staining using polyclonal
antibodies directed against YB-1 (brown). All tissues were counterstained with hematoxyline (blue). Upper left (green box): non-neoplastic brain
tissue did not exhibit any YB-1 expression. Tissues prepared from GBM patients (red boxes) showed varying expression patterns. Upper right: no
YB-1 expression, lower left: cytoplasmic YB-1 expression, lower right: nuclear YB-1 expression.
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Ad-Delo3-RGD in a mouse orthotopic TMZ resistant
GBM/CSC brain tumor model
To evaluate the potential of Ad-Delo3-RGD in affecting
GBM growth, we established a mouse orthotopic brain
tumor model using TMZ-resistant R28 brain CSC cells.
These cells express high levels of MGMT (Figure 1B) as
well as of aldehyde dehydrogenase (ALDH) 1A1 [43],
both proteins procuring resistance to TMZ. R28-derived
GBM-bearing mice were treated with either TMZ, were
intratumorally injected with Ad-Delo3-RGD or achieved
a combination therapy. The two groups treated with
Ad-Delo3-RGD (either with or without additional TMZ
treatment) survived significantly longer than mice
which achieved solely TMZ or were mock-(PBS)-treated
(p < 0.001). Median survival time increased from 125 days
in mock treated mice up to 176 days in Ad-Delo3-RGD
treated mice. 167 days post treatment none of the mice
receiving an intratumoral PBS (mock) injection or were
treated solely with TMZ (0/15) survived, whereas 50%
(7/14) of the mice receiving an intratumoral Ad-Delo3-
RGD injection were still alive. TMZ treatment of mice
did not show any significant effect in none of the treat-
ment groups (Figure 6A). Histopathological evaluation
of mock-treated tumors (Figure 6B, upper left) as well
as of tumors of TMZ treated mice (Figure 6B, upper
middle) showed a similar histopathological appearance.
In these mice, polymorphic, highly mitotic tumor tissue
was detectable. In contrast, tumors of mice achieving
intratumoral Ad-Delo3-RGD injections were smaller,
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Figure 3 Ad-Delo3-RGD replicates in and kills brain CSC lines similarly to wild type adenovirus. (A) PCR analysis of Ad-Delo3-RGD preparation
demonstrates the absence of E1A13S sequences and for this the absence of RCA in purified Ad-Delo3-RGD. (B) PCR-based assessment of virus replication
of an E1A-deleted adenovirus (dl703), Ad-Delo3-RGD or Ad-WT in R11, R28 and R40 CSC. Ad-Delo3-RGD replicates around 130 fold (R11) or 345 fold (R28)
better in CSC than dl703. In R40 brain CSC line, Ad-Delo3-RGD replicates around 620 fold better than dl703, and even 4.3 fold better than Ad-WT. Viral
DNA for PCR amplification was isolated from infected cells 4 h (white bars) or 72 h (grey bars) post infection. Values are given as relation of adenoviralf i b e r
DNA copies to β-actin copies. Columns represent the mean of 3 measurements (C) Tumorspheres of brain CSC lines are destroyed by the YB-1 dependent
adenovirus Ad-Delo3-RGD. Brain CSCs were seeded in 6-well plates and 24 h later infected with 50 MOI of the indicated virus, or were treated
with 100 μMT M Z .5 –7 days later morphology was studied microscopically (magnification = 100 x). Control: untreated CSC spheres.
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http://www.translational-medicine.com/content/11/1/216presenting high numbers of apoptotic cells and less vital
tumor cells (Figure 6B, upper right). However, in virus
treated animals no toxicity or inflammation could be
observed in any non-neoplastic part of the brain adja-
cent to the tumor including the subventricular zone
(Figure 6B, lower left), cerebellum (Figure 6B, lower
middle) and cortex (Figure 6B, lower right).
Discussion
It is well established that GBM show increased activa-
tion of different signaling pathways including PI3-K/
AKT and MAPK/ERK. Signaling through both ERK and
AKT is implicated in drug resistance and cell invasion
[44,45]. The same has been described for CSC of the
brain. Drug resistance and invasive growth are features
that make this tumor so difficult to treat. Beside this,
identification of CSC in GBM has been found to be of
prognostic value [46,47].
Several lines of evidence have indicated a close relation-
ship of YB-1 function and PI3-K/AKT and MAPK/ERK
mediated signaling in tumor cells, including direct phos-
phorylation of YB-1 (serine
102) by AKT and by RSK, a
downstream player of the MAPK signaling cascade,
thereby affecting cellular localization and biological func-
tion of YB-1 [13,48]. YB-1 in its function as a transcription
factor regulates gene expression by binding to promoter
regions containing a Y-box motif. Amongst others, YB-1
activates gene expression of the epidermal growth factor
receptor (EGFR), matrix metalloproteinase 2 (MMP-2)
and of the receptor tyrosine kinase c-MET, all this associ-
ated with tumor cell adhesion, invasion and metastasis.
Thus, YB-1 could be positioned as a key player in the PI3-
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Figure 4 Ad-Delo3-RGD efficiently kills brain CSC lines under normoxic and hypoxic conditions. In a clonogenic dilution assay, adenovirally
infected CSC were diluted in 1:10 steps in stem cell-permissive DMEM-F12 medium and incubated for 4–6 weeks until the medium turned yellow due
to metabolic acidification. Control: untreated; TMZ: temozolomide [100 μM]; AdE1-minus: replication-deficient adenovirus dl703; Ad-WT: wild type
adenovirus; Ad-Delo3-RGD: YB-1 dependent oncolytic adenovirus. Red color indicates no metabolic activity due to low cell survival whereas yellow
color indicates high metabolic activity due to treatment failure, indicating cell survival. A representative experiment is shown.
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observation, that YB-1 expression is regulated by Twist,
which in turn is transcriptionally induced by STAT3. Both
are known to play an important role in epithelial to mes-
enchymal transition (EMT), maintenance of cancer initiat-
ing cells and multidrug resistance [50,51].
The importance of YB-1 in conferring multidrug resist-
ance is well documented [13,16]. The role of YB-1 in can-
cer initiation has, until recently, not been investigated.
Dunn and colleagues have shown that blocking YB-1 pro-
tein expression delayed tumor onset in mice. In addition,
they demonstrated that YB-1 is involved in tumor initiat-
ing surface marker expression, including CD44 in breast
cancer initiating cells. Based on these findings, they postu-
late that MAPK/RSK phosphorylation and activation of its
downstream targets, including YB-1, promote a cancer
initiating phenotype [20].
I naf i r s ts t e p ,w ee x a m i n e dt h ea b o v em e n t i o n e d
pathways, which turned out to be generally activated in
brain CSC (Figure 1A). Next, we studied the down-
stream target YB-1. We found considerable expression
as well as phosphorylation and therefore activation of
YB-1 in all brain CSC and GBM cell lines analyzed so
far, but not in non-neoplastic brain tissue (Figure 2).
This is in line with previous studies that evaluated YB-1
expression in pediatric primary GBM and non-neoplastic
brain tissue [29]. However, even if the major fraction of
GBM expresses YB-1, its expression level and subcellular
localization varies among tumors of different patients
(Figure 2C). Since it is known that YB-1 will be up-
regulated as well as activated by phosphorylation and
nuclear localization in patients who initially have been
treated with radio-chemotherapy, the detected variability
of YB-1 expression in different GBM specimen may be a
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Figure 5 siRNA mediated downregulation of YB-1 reduced viral replication in infected CSC. (A) Immunblot of YB-1 in R28 cells 48 h after
transfection with either control- or YB-1 specific siRNA. Tubulin serves as a loading control. (B) Quantification of YB-1 expression in R28 knockdown
cells (normalized to tubulin). (C) R28 cells were transfected with control siRNA (siCo) or siRNA against YB-1 (siYB-1), respectively. 48 h later, cells were
infected with 50 MOI of either Ad-WT or Ad-Delo3-RGD. Cells were harvested and DNA was isolated 4 h or 72 h after infection. Adenoviral DNA copy
numbers as a degree of viral replication were assessed using real-time PCR. siRNA mediated knockdown of YB-1 by reduced Ad-WT replication in
infected R28 cells to 76% and Ad-Delo3-RGD-replication to 42%. (D) Ad-Delo3-RGD does not replicate efficiently in human immortalized
astrocytic SV-GA cells. Data represent the final viral titer as pfu/ml. Viral titers were determined by hexon titer assay from lysates of infected U87MG and
SV-GA cells. 175.000 cells were infected with 10 MOI of Ad-WT or Ad-Delo3-RGD under serum-starved conditions (0.5% fetal bovine serum, no growth
supplements) for 20 min. In the case of equal particle formation in both cell lines the ratio is = 1. Thus, a ratio >1 indicates higher viral production in
astrocytes compared to U87MG cells. A ratio < 1 indicates lower viral production in astrocytes compared to U87MG cells (n=3, ** p=0.0028,)
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http://www.translational-medicine.com/content/11/1/216result of different chemotherapy approaches and different
cycles of chemotherapy the patients received. This fact
makes Ad-Delo3-RGD treatment of patients with recur-
rent GBM, who achieved chemo-radiotherapy, an interest-
ing virotherapeutic strategy, since notably these patients
will present high amounts of activated YB-1 in their tumor
cells.
On the one hand, YB-1 like Twist is capable to induce
EMT in some tumor entities [52] but on the other hand,
EMT has been reported to be linked to the gain of epi-
thelial stem cell properties [53]. In addition, migrating
GBM cells showing a stemness-like phenotype are
characterized by expressing high levels of CD44 and low
levels of programmed cell death protein (PDCD)4, a
factor known to inhibit YB-1 expression [54]. Taken to-
gether, our data support the idea of Dunn and colleagues
that YB-1 might promote a cancer initiating phenotype.
However, the role of YB-1 in brain CSC tumorigenicity
remains to be studied in detail and was beyond the
scope of this work.
It has been reported that embryonal carcinoma stem
cells support adenoviral replication more efficiently than
differentiated derivatives, hypothesizing that a cellular
factor with E1A-like activity is regulated during differenti-
a t i o ni ns t e mc e l l s[ 5 5 ] .W eh a v ep r e v i o u s l yr e p o r t e dt h a t
the recombinant adenovirus Ad-Delo3-RGD, containing a
certain deletion in the E1A gene, replicates in nuclear YB-1
positive cancer cells [27]. We used Ad-Delo3-RGD which
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Figure 6 R28-GBM bearing mice treated with Ad-Delo3-RGD showed prolonged survival without any sign of toxicity. (A) Survival data of R28
CSC-derived GBM bearing mice treated as indicated are plotted using the Kaplan-Meier method. p-values were determined using the log-rank test.
R28-GBM bearing mice treated with Ad-Delo3-RGD or Ad-Delo3-RGD plus TMZ survived significantly longer than mice treated with TMZ or PBS alone.
(PBS vs. Ad-Delo3-RGD, p = 0.007; PBS vs. TMZ + Ad-Delo3-RGD, p = 0.013; TMZ vs. Ad-Delo3-RGD, p = 0.023; TMZ vs. TMZ + Ad-Delo3-RGD, p = 0.035.
(B) Histopathological analyses of tumors (upper panel) and of non-neoplastic tumor adjacent brain tissue of Ad-Delo3-RGD-treated mice (lower panel).
Upper left: PBS-treatment; upper middle: TMZ-treatment; upper right Ad-Delo3-RGD-injection. Lower panel: Ad-Delo3-RGD shows no toxicity in any
non-neoplastic part of the brain including subventricula zone (left), cerebellum (middle) and cortex (right). 5 μm sections were stained with H&E.
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http://www.translational-medicine.com/content/11/1/216contained a RGD motif to increase infectivity in glioma
cells. However, brain CSC show high CAR expression;
hence the infection of CSC occurs also independent from
RGD-fiber modification (data not shown). Here we dem-
onstrate efficient viral replication in and cell killing of
brain CSC lines by Ad-Delo3-RGD under normoxic and
even under hypoxic conditions (Figure 3, 4). OAV like
Ad-Delo3-RGD have displayed the potential to efficiently
kill not only differentiated cancer cells, but also CSC,
including CD44
high/CD24
low cancer breast cells and
CD133
high glioma CSC [25,26]. However, this is the first
report showing that YB-1, which is highly expressed in
CSC lines, facilitates adenovirus replication. This is in line
with recently published data illustrating that YB-1 is com-
monly expressed in primary brain CSC and that its expres-
sion increased with tumor grade [56].
We next examined the therapeutic anti-tumor efficacy
of Ad-Delo3-RGD in an intracranial, orthotopic mouse
model using MGMT expressing, TMZ-resistant R28 CSC
(Figure 1B). This GBM animal model reflects clinical real-
ity better than using established GBM cell lines. Radio-
therapy in combination with the alkylating agent TMZ is
currently the standard of care for GBM. GBM expressing
MGMT due to an unmethylated MGMT promoter show
resistance to treatment with TMZ [57,58]. Furthermore,
patients presenting an unmethylated MGMT promoter do
not or only marginally benefit from TMZ treatment [59].
Whereas the treatment of R28-GBM bearing mice with
TMZ had, as expected no effect, intratumoral injection
of Ad-Delo3-RGD significantly prolonged survival of
mice. No further increase in survival was observed when
Ad-Delo3-RGD injection was combined with TMZ treat-
ment (Figure 6A). This was not unexpected since initial
in vitro experiments using R28 cells did not indicate any
additive or even synergistic inhibition of brain CSC
growth when adenoviral infection was combined with
TMZ treatment (data not shown). However, the results
are in contrast to published data using TMZ resistant mel-
anoma cell of unknown MGMT status [60] or established
GBM cell lines [28]. In this context it is mentionable that
ionizing radiation (IR) strongly induces YB-1 phosphoryl-
ation, enhances repair of DNA double-stranded breaks
and affects cell survival [61]. Since current standard of
care for patients with GBM includes IR, which is a strong
activator of the PI3-K/AKT and MAPK/ERK pathways
and promote radio-resistance by activation of the DNA
damage response [62,63], it would be interesting or even
necessary to include IR in future combinatorial treatment
studies.
During treatment of R28-GBM bearing mice, we
intratumorally applied 3 x 10
8 pfu Ad-Delo3-RGD. This
is, compared to human, a lower virus load than the well-
tolerated dose of the OAV ONYX-015 evaluated for hu-
man [64]. Using this dose, microscopic examinations of
brain tissues of Ad-Delo3-RGD treated mice showed no
signs of inflammation or other related toxicity in adjacent,
tumor-surrounding healthy brain, including the sub-
ventricular zone, cerebellum and cerebrum, indicating
the safety of this YB-1 based virotherapy approach. In
addition, our experiments showed, that (i) replication of
Ad-Delo3-RGD depends on the presence of YB-1 in can-
cer stem-like cells, and (ii) Ad-Delo3-RGD only marginally
replicates in human immortalized astrocytes (Figure 5).
The fact that YB-1 is highly expressed in cancer cells com-
pared to non-neoplastic brain tissue suggests that an YB-1
based virotherapy approach has a high therapeutic index.
However, extensive toxicity and biodistribution studies are
still necessary to confirm the safety of Ad-Delo3-RGD.
Conclusion
The results reported here demonstrate that YB-1 is
highly expressed in brain cancer stem cell lines and
unambiguously, that these cells were efficiently killed by
YB-1 dependent OAV in vitro, leaving non-neoplastic
astrocytes unattached. Mean survival of Ad-Delo3-RGD
treated R28-bearing mice was significantly longer than
that of control mice. To develop new virotherapeutic
strategies for GBM, our data are of clinical relevance
since it is believed that brain CSC are critical for GBM
maintenance and recurrence. In addition, YB-1 expres-
sion is linked to multidrug- and radio-resistance and has
been repeatedly described to be a predictive biomarker.
Even knowing that YB-1 will be upregulated by chemo-
as well as radiotherapy, YB-1 analysis of GBM biopsies
might improve the therapeutic decision making process
in a clinical setting and can help to identify patients who
will benefit from novel YB-1 based virotherapy.
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